Table 3.

Univariate and Multivariate Survival Analyses of Patients with EBV-Negative/MMR-Proficient Advanced Gastric Cancer

Factor	Overall survival						Disease-free survival
	Univariate			Multivariate			Univariate			Multivariate
	HR (95% CI)	p-value		HR (95% CI)	p-value		HR (95% CI)	p-value		HR (95% CI)	p-value
Age		<0.001			<0.001			0.656			0.636
≤55 yr	1			1			1			1
>55 yr	1.374 (1.156–1.633)			1.547 (1.258–1.901)			0.925 (0.762–1.123)			1.057 (0.842–1.326)
Sex		0.099			0.248			0.036			0.519
Male	1			1			1			1
Female	1.156 (0.973–1.374)			1.128 (0.920–1.384)			1.276 (1.047–1.555)			1.080 (0.855–1.365)
Differentiation		<0.001			0.220			<0.001			0.373
Differentiated	1			1			1			1
Undifferentiated	1.536 (1.262–1.869)			1.198 (0.897–1.600)			1.759 (1.387–2.231)			1.175 (0.824–1.676)
Lauren classification		0.008			0.546			<0.001			0.180
Intestinal or mixed	1			1			1			1
Diffuse	1.260 (1.063–1.493)			1.083 (0.836–1.403)			1.539 (1.260–1.880)			1.235 (0.908–1.680)
Pathologic T stage		<0.001			<0.001			<0.001			<0.001
2/3	1			1			1			1
4	2.549 (2.142–3.035)			2.159 (1.763–2.644)			3.124 (2.541–3.841)			2.397 (1.887–3.045)
LVI		<0.001			0.002			<0.001			0.008
Absent	1			1			1			1
Present	2.167 (1.818–2.584)			1.392 (1.128–1.718)			2.210 (1.805–2.706)			1.387 (1.090–1.763)
Lymph node metastasis		<0.001			<0.001			<0.001			<0.001
Absent	1			1			1			1
Present	3.243 (2.591–4.061)			2.405 (1.824–3.172)			3.800 (2.887–5.001)			2.444 (1.773–3.369)
CDX-1		0.003			0.019			0.011			0.013
Negative	1			1			1			1
Expressed	0.756 (0.629–0.909)			0.780 (0.635–0.960)			0.759 (0.614–0.938)			0.741 (0.585–0.938)
CDX-2		0.001			0.009			0.002			0.049
Negative	1			1			1			1
Expressed	0.733 (0.614–0.876)			0.759 (0.618–0.932)			0.722 (0.588–0.885)			0.789 (0.624–0.999)

EBV, Epstein-Barr virus; MMR, mismatch repair; HR, hazard ratio; CI, confidence interval; LVI, lymphovascular invasion; CDX, caudal type homeobox.